SilverStream Medical

SilverStream Medical Overview

Silverstream Medical, an Israeli company established in 2001 and reestablished in November 2021 after a successful management buyout, focused on eliminating surgical site infections (SSIs), a major cause of hospital readmissions and mortality. SSIs affect 5% of surgeries annually in the US alone, with even higher rates globally. Silverstream Medical is a leading medical device company dedicated to developing and commercializing innovative solutions for the prevention of SSI and wound care, offering a range of patented products. The company operates globally with a US subsidiary, Silverstream Medical LLC, and a robust distribution network spanning 22 countries, adhering to international quality standards including ISO 13485:2016 certification. Our flagship product, Silverstream, is an FDA-approved solution with nearly 500,000 successful treatments and is commercially available in multiple countries. It actively prevents infections by destroying biofilm and inhibiting bacteria growth. We've proven our effectiveness in post-operative care, for which we currently have FDA approval for our innovative silver-based solution, and are now expanding into the in-surgical SSI market, projected to reach $7.5 billion by 2030, aiming to prevent infections in real-time during surgical procedures. We are pursuing clinical trials to demonstrate the safety and efficacy of our technology in this area. The SilverStream solution is set to become the dominant global choice for surgical disinfection, revolutionizing surgical outcomes worldwide. With this expansion, we project revenues exceeding tens of millions of USD within the next three years. Driven by a vision of a world free from SSI-related complications and a commitment to improving patient outcomes and optimizing healthcare resources, Silverstream Medical is poised to become a global leader in the fight against surgical site infections.

Cumulative Funding Raised Over Time ($)

Latest News

Jan 7, 2025 · www.linkedin.com

🎉 Singapore, We're Certified! 🎉 SilverStream Solution Arrives! We are thrilled to announce that SilverStream Solution is officially certified by Health Sciences Authority (HSA) Singapore! 🎉 This milestone marks another step in expanding our global presence, bringing our innovative wound care solutions to more healthcare professionals and patients worldwide. 🌏 We're excited to partner with MedAiD Solutions Pte Ltd, our partner, to ensure a successful launch in Singapore. Together, we're comm

Jan 5, 2010 · en.globes.co.il

growth-positive

Wound care co EnzySurge raises $4.1m

EnzySurge, a wound care treatment developer, has raised $11 million from private investors, including the present round. The companys valuation is $20 million. EnzySurge plans to use the investment to speed up penetration of the US market and expand marketing efforts to Europe. They have received an offer for an IPO on the Tel Aviv Stock Exchange but have not yet decided whether to go this route. EnzySurge recently obtained FDA approval for its SilverStream solution for wound management. The company aims to provide treatment for various types of wounds, including ulcers, burns, and cuts.

InvestmentPublic TradingExpand

Dec 22, 2009 · www.calcalist.co.il

growth-positive

חברת אנזיסרג' גייסה 2.5 מיליון דולר

Israeli life sciences company EnzySurge has raised $2.5 million in funding from private investors. The company has raised a total of $10 million to date. EnzySurge develops solutions for the treatment of chronic wounds. The wound care market is estimated to be worth $4 billion per year. Following FDA approval, EnzySurge can now sell its developed active healing solution without a prescription, opening up a new market for wound care products. The company plans to use the investment to continue its penetration into the American market. EnzySurge recently completed a successful clinical trial in several Israeli hospitals, showing improvement in healing chronic wounds and reducing healing time.

Investment

Jan 23, 2008 · www.biospace.com

growth-positive

EnzySurge Raises US$2 Million Proceeds Will be Used to Accelerate Market Launch of its Wound Care Product in 2008 BioSpace

EnzySurge Ltd. expects to expand its recent $2 million private investment round to $3 million. The company plans to use the additional capital to accelerate the FDA approval process and expand its marketing efforts for its DermaStream product line, which offers innovative solutions for chronic wound management. EnzySurges technology allows for continuous streaming of therapeutic solutions throughout all phases of wound treatment. The company aims to launch its first product in the second half of 2008. Chronic wounds affect a significant portion of the population and current treatment options are expensive and only partially effective. EnzySurges solution aims to improve healing and reduce treatment costs. The company recently completed a clinical study demonstrating safety and accelerated wound closure with its enzymatic solution.

InvestmentExpand

Dec 31, 2006 · en.globes.co.il

growth-positive

Wound healing co EnzySurge raises $1.7m

Israeli start-up EnzySurge has closed its third financing round, raising $1.7 million from private investors at a value of $7 million. The company has developed treatments for chronic wounds and recently received FDA approval for its product named DermaStream. EnzySurge has also completed the development of a new solution-based treatment called EnzyStream, which is currently awaiting FDA approval. The market for treatments for chronic wounds is growing and EnzySurge is conducting safety and efficacy trials for its products.

Investment

Funding

Team Members

1

Employees: 1-10

Web & Social Links

Locations

Ha-Rav Shalom Shabazi St 26, Rosh Haayin, Israel

Photos & Videos

3 item(s)

SilverStream Medical Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info